Form 4 for ANVS Annovis Bio, Inc.
Accepted 2022-01-18 00:00:00 ET · period of report 2022-01-14 · accession 0001104659-22-005059 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-18 | 2022-01-14 | ANVS | Maccecchini Maria-Luisa | Pres, CEO, Dir, 10% | M - OptEx | $0.14 | +33.0K | 987.7K | +3% | +$4,614 |
| D | 2022-01-18 | 2022-01-14 | ANVS | Maccecchini Maria-Luisa | Pres, CEO, Dir, 10% | M - OptEx | $0.00 | -33.0K | 52.8K | -38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-14 | M | A | 32,959 | $0.14 | 987,734 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-01-14 | M | D | 32,959 | $0.00 | 52,755 | D | $0.14 · — to 2027-04-01 | 32,959 Common Stock | (F1) All of the shares underlying the option are fully vested and exercisable. |